Welcome to our dedicated page for ICON PLC SEC filings (Ticker: ICLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ICON PLC’s SEC reports can feel as dense as a clinical trial protocol—buried inside the 10-K are pages on backlog conversion rates, post-acquisition synergies, and laboratory service margins. Hunting for a single note on patient-recruitment risk or integration costs consumes precious time. Stock Titan’s platform surfaces the answers instantly, giving you an AI-powered shortcut to ICON PLC SEC filings explained simply.
Whether you need an ICON PLC annual report 10-K simplified to spot goodwill impairment triggers, or an ICON PLC quarterly earnings report 10-Q filing to track revenue by Phase III study, every document arrives in real time from EDGAR. Our AI breaks down:
- Form 4 insider transactions—get ICON PLC Form 4 insider transactions real-time alerts and visualize buying or selling before key data readouts.
- 8-K material events—see “ICON PLC 8-K material events explained”, from large contract wins to unexpected trial discontinuations.
- Proxy statements—quickly compare ICON PLC proxy statement executive compensation against peer CROs.
Practical use cases follow naturally: monitor ICON PLC executive stock transactions Form 4 ahead of earnings, compare backlog growth quarter-over-quarter, or gauge acquisition integration costs without wading through footnotes. From "understanding ICON PLC SEC documents with AI" to "ICON PLC earnings report filing analysis", Stock Titan equips life-sciences investors with clear summaries, expert context, and searchable, always-current filings—so you can focus on decisions, not document hunts.
ICON plc (ICLR) filed a Form 6‑K with Q3 2025 results and updates. Revenue was $2,042,812 thousand for the quarter and $6,061,501 thousand for the nine months. Q3 net income was $2,355 thousand (basic EPS $0.03) versus $197,128 thousand a year ago, driven by a non‑cash goodwill impairment of $165,300 thousand recorded in the quarter. Income from operations was $86,584 thousand versus $285,434 thousand in Q3 2024.
The company executed significant buybacks: 4,504,330 shares were redeemed in 2025 for $750,000 thousand in total consideration, with remaining authorization of $750,000 thousand as of October 23, 2025. Cash and cash equivalents were $468,888 thousand, and total debt was $3,424,129 thousand at September 30, 2025. Net cash provided by operating activities for the nine months was $802,043 thousand.
ICON recorded restructuring charges of $82,296 thousand year‑to‑date and improved accumulated other comprehensive loss to $(86,944) thousand. Unsatisfied performance obligations were approximately $14.0 billion, with 51% expected to be recognized over the next 12 months. The company noted a BARDA stop work notice affected a large COVID vaccine study, with about half of the planned 10,000 participants enrolled and continued follow‑up per protocol.
ICON plc (ICLR) insider filed a Form 144 to sell 18,901 common shares with an aggregate market value of $3,594,781.19. The shares are scheduled for sale on or about 10/02/2025 on NASDAQ.
The filing shows the 18,901 shares were acquired on 10/01/2025 as restricted stock that vested under a registered plan and were issued by the issuer for services rendered. The filing reports 77,772,130 shares outstanding and indicates no securities sold by the filer in the past three months.
FAQ
What is the current stock price of ICON PLC (ICLR)?
What is the market cap of ICON PLC (ICLR)?
